Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 18:36:36时区推断·⟳ 抓取 18:37:03·⚡ 决策 07-27 18:38:38 +1m35s·92.0 天前
Kura公布肾癌联合疗法FIT-001一期a更新数据
Kura Oncology（KURA.US）披露darlifarnib联合cabozantinib在晚期透明细胞肾癌Phase 1a中ORR约33%–50%、 pooled PFS 13个月，临床方向偏正面。
📄 原文Investing.com↗ 原文
Kura reports phase 1a trial results for kidney cancer treatment
Oil prices tumble over 8% amid halt to fighting between U.S., Iran SAN DIEGO - Kura Oncology, Inc. (NASDAQ:KURA) announ…
不做 Kura Oncology（KURA.US）
不做：虽然Phase 1a数据方向偏正面，但7月14日已预告、4月已有同项目数据，且随机Phase 1b仍在入组、注册性研究到2028年才启动，当前缺少足以支撑盘前追多的近期商业化或估值重定价增量。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司提前公告将在2026 KCRS口头报告FIT-001 Phase 1a更新结果，并说明随机Phase 1b仍在进行、注册性研究计划2028年启动。
- 媒体转述Kura公布34例cabozantinib-naive患者ORR 33%–50%、pooled PFS 13个月和安全性可管理。市场反应:美股仍处盘前，公开网页报价显示盘前约10.37美元、较前收小幅下跌。
关键理由
- Kura Oncology（KURA.US）披露darlifarnib联合cabozantinib在晚期透明细胞肾癌Phase 1a中ORR约33%–50%、 pooled PFS 13个月，临床方向偏正面。
- 该项目仍处Phase 1a/1b，随机Phase 1b仍在入组，注册性研究计划到2028年才启动，距离商业化和收入贡献很远。
- 公司目前约9.2亿美元市值、年销售基数约6748万美元，本事件没有新增可量化订单或近期收入增量，更多是管线可选价值更新。
主要风险
- 7月14日公司已预告KCRS将披露FIT-001长期随访更新，4月和5月已有同一项目/机制的临床数据发布，新鲜度不足。
- 早期小样本肿瘤数据容易在会议披露后高开低走，且后续关键读出要等随机Phase 1b和2028年注册性研究。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-04-17 · 影响 weakens
4月已有同一FIT-001肾癌数据披露，削弱7月27日作为全新催化的预期差。
检索:Kura Oncology darlifarnib FIT-001 prior data April 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-14 · 影响 weakens
随机Phase 1b仍在进行，注册性研究计划2028年启动，距离可量化商业化现金流较远。
检索:Kura Oncology FIT-001 registrational study 2028 Phase 1b ongoing 原文 ↗
原文全文
展开原文 · 1,881 字
Oil prices tumble over 8% amid halt to fighting between U.S., Iran
SAN DIEGO - Kura Oncology, Inc. (NASDAQ:KURA) announced results from its Phase 1a FIT-001 clinical trial evaluating darlifarnib combined with cabozantinib in patients with advanced clear cell renal cell carcinoma, according to a press release statement.
The trial enrolled 34 cabozantinib-naïve patients with locally advanced or metastatic clear cell renal cell carcinoma who had received prior treatment. Objective response rates ranged from 33% to 50% across different darlifarnib dose levels. Median progression-free survival was 13 months across pooled dose levels.
The safety analysis included 72 renal cell carcinoma patients. The combination’s safety profile was consistent with the individual agents’ known profiles. Neutropenia was managed through dose interruption, reduction and supportive care following the initial dose-limiting toxicity period.
The company is enrolling patients in the United States and European Union for the randomized Phase 1b portion of FIT-001. This portion compares darlifarnib plus cabozantinib against cabozantinib alone to determine the recommended Phase 3 dose. Kura plans to initiate a registrational study in 2028.
Darlifarnib is a farnesyl transferase inhibitor that inhibits farnesylation of RHEB, resulting in selective mTORC1 inhibition. The mechanism is designed to enhance activity of VEGFR-targeted therapies including cabozantinib.
The results were presented at the 2026 Kidney Cancer Research Summit in Boston on Monday.
Kura Oncology is a biopharmaceutical company developing precision medicines for cancer treatment. The company commercializes KOMZIFTI, an FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN DIEGO - Kura Oncology, Inc. (NASDAQ:KURA) announced results from its Phase 1a FIT-001 clinical trial evaluating darlifarnib combined with cabozantinib in patients with advanced clear cell renal cell carcinoma, according to a press release statement.
The trial enrolled 34 cabozantinib-naïve patients with locally advanced or metastatic clear cell renal cell carcinoma who had received prior treatment. Objective response rates ranged from 33% to 50% across different darlifarnib dose levels. Median progression-free survival was 13 months across pooled dose levels.
The safety analysis included 72 renal cell carcinoma patients. The combination’s safety profile was consistent with the individual agents’ known profiles. Neutropenia was managed through dose interruption, reduction and supportive care following the initial dose-limiting toxicity period.
The company is enrolling patients in the United States and European Union for the randomized Phase 1b portion of FIT-001. This portion compares darlifarnib plus cabozantinib against cabozantinib alone to determine the recommended Phase 3 dose. Kura plans to initiate a registrational study in 2028.
Darlifarnib is a farnesyl transferase inhibitor that inhibits farnesylation of RHEB, resulting in selective mTORC1 inhibition. The mechanism is designed to enhance activity of VEGFR-targeted therapies including cabozantinib.
The results were presented at the 2026 Kidney Cancer Research Summit in Boston on Monday.
Kura Oncology is a biopharmaceutical company developing precision medicines for cancer treatment. The company commercializes KOMZIFTI, an FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。